New Approaches for Managing Postoperative Intraocular Inflam -

Overview
Research indicates that sustained-release implants may have better efficacy and fewer systemic side effects when treating posterior segment uveitis than other corticosteroid delivery options or alternative nonsteroidal treatments. To provide the best treatment possible for patients undergoing eye surgery, ophthalmologists must have a thorough understanding of all available options and their benefits and challenges.
This webinar will include a lively discussion on current postoperative therapies, novel approaches that may improve efficacy and adherence, pivotal clinical trial data, and the importance of personalized treatment plans.
This activity is supported by an independent medical education grant from EyePoint Pharmaceuticals.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Describe the limitations of postoperative topical corticosteroids
- Categorize the novel approaches to manage and/or prevent posterior inflammation that may improve efficacy and adherence
- Interpret pivotal clinical trial data leading to FDA approvals of sustained-release devices for posterior segment inflammation
- Create personalized treatment plans based on patient needs and preferences
- Discuss the literature on alternative therapies, including their safety, efficacy, and ideal patient selection
Accreditation
Provided by Evolve Medical Education
Accreditation Statement
Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Evolve designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participation Method
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Faculty and Disclosures
Daniel F. Kiernan, MD, FACS
Vitreoretinal Surgeon
The Eye Associates
Sarasota, FL

Nathan M. Radcliffe, MD
Glaucoma Specialist
New York Eye Surgery Center
New York, NY

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Daniel F. Kiernan, MD, FACS, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, EyePoint Pharmaceuticals, and Physician Recommended Nutraceuticals. Grant/Research Support: EyePoint Pharmaceuticals and Gyroscope. Speaker’s Bureau: Alimera, Allergan, EyePoint Pharmaceuticals, Mallinckrodt, Novartis, Physician Recommended Nutraceuticals, Regeneron Pharmaceuticals, and Spark Therapeutics.
Nathan M. Radcliffe, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie Pharmaceuticals, Alcon Vision, Alimera Sciences, Allergan, Bausch + Lomb, Beaver-Visitec International, Carl Zeiss Meditec, CATS, Ellex, ELT Sight, Equinox, Eyepoint Pharmaceuticals, Glaukos, Iridex, Ivantis/Kala Pharmaceuticals, Lumenis, New World Medical, Novartis, Ocular Science, Ocular Therapeutix, Omeros, Quantel Medical, Reichert, Santen, Shire Sight Sciences, Spyglass Thea, and ViaLase. Speaker’s Bureau: Aerie Pharmaceuticals, Alcon Vision, Alimera Sciences, Allergan, Bausch + Lomb, Beaver-Visitec International, Eyepoint Pharmaceuticals, Glaukos, Iridex, Ivantis\Kala Pharmaceuticals, Lumenis, New World Medical, Novartis, Reichert, and Sight Sciences. Stock/Shareholder: CATS, ELT Sight, Equinox, Ivantis, Sight Sciences, and Spyglass.
The Evolve staff and planners have no financial relationships with commercial interests.
Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or EyePoint Pharmaceuticals.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 01/05/2022
Expiration Date: 01/12/2022

Daniel F. Kiernan, MD, FACS

Guest

Nathan M. Radcliffe, MD

Guest

Recommended

Title

Share on ReachMD